Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.

Saved in:
Bibliographic Details
Title: Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.
Authors: Fiskus W; Divisions of Cancer Medicine, Pathology-Lab Medicine and Discovery Science, The University of Texas, MD Anderson Cancer Center, Houston, TX., Masarova L; Divisions of Cancer Medicine, Pathology-Lab Medicine and Discovery Science, The University of Texas, MD Anderson Cancer Center, Houston, TX., Mill CP; Divisions of Cancer Medicine, Pathology-Lab Medicine and Discovery Science, The University of Texas, MD Anderson Cancer Center, Houston, TX., Birdwell CE; Divisions of Cancer Medicine, Pathology-Lab Medicine and Discovery Science, The University of Texas, MD Anderson Cancer Center, Houston, TX., Das K; Divisions of Cancer Medicine, Pathology-Lab Medicine and Discovery Science, The University of Texas, MD Anderson Cancer Center, Houston, TX., Hou H; Divisions of Cancer Medicine, Pathology-Lab Medicine and Discovery Science, The University of Texas, MD Anderson Cancer Center, Houston, TX., Davis JA; Divisions of Cancer Medicine, Pathology-Lab Medicine and Discovery Science, The University of Texas, MD Anderson Cancer Center, Houston, TX., Jain A; Mass Spectrometry Proteomics Core, Baylor College of Medicine, Houston, TX., Malovannaya A; Mass Spectrometry Proteomics Core, Baylor College of Medicine, Houston, TX., Manshouri T; Divisions of Cancer Medicine, Pathology-Lab Medicine and Discovery Science, The University of Texas, MD Anderson Cancer Center, Houston, TX., Dunbar A; Divisions of Cancer Medicine, Pathology-Lab Medicine and Discovery Science, The University of Texas, MD Anderson Cancer Center, Houston, TX., Sharma S; Divisions of Cancer Medicine, Pathology-Lab Medicine and Discovery Science, The University of Texas, MD Anderson Cancer Center, Houston, TX., Kadia TM; Divisions of Cancer Medicine, Pathology-Lab Medicine and Discovery Science, The University of Texas, MD Anderson Cancer Center, Houston, TX., DiNardo CD; Divisions of Cancer Medicine, Pathology-Lab Medicine and Discovery Science, The University of Texas, MD Anderson Cancer Center, Houston, TX., Bose P; Divisions of Cancer Medicine, Pathology-Lab Medicine and Discovery Science, The University of Texas, MD Anderson Cancer Center, Houston, TX., Pemmaraju N; Divisions of Cancer Medicine, Pathology-Lab Medicine and Discovery Science, The University of Texas, MD Anderson Cancer Center, Houston, TX., Loghavi S; Divisions of Cancer Medicine, Pathology-Lab Medicine and Discovery Science, The University of Texas, MD Anderson Cancer Center, Houston, TX., Su X; Divisions of Cancer Medicine, Pathology-Lab Medicine and Discovery Science, The University of Texas, MD Anderson Cancer Center, Houston, TX., Rampal RK; Memorial Sloan Kettering Cancer Center, New York, NY., Törngren M; Active Biotech AB, Lund, Sweden., Bhalla KN; Divisions of Cancer Medicine, Pathology-Lab Medicine and Discovery Science, The University of Texas, MD Anderson Cancer Center, Houston, TX.
Source: Blood advances [Blood Adv] 2025 Nov 11; Vol. 9 (21), pp. 5598-5609.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2025016898